Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.40 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.40 |
| ▸ | FDPS | P14324 | 10/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.35 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12806713 | 0.88 | LPAR3 (0.39) | LPAR3LPAR1LPAR2FDPSMEN1 | |
| SCHEMBL26250157 | 0.87 | LMNA (0.41) | LPAR3LPAR1LPAR2FDPSLMNA | |
| SCHEMBL16995440 | 0.85 | LPAR3 (0.41) | LPAR3LPAR1LPAR2FDPSMEN1 | |
| SCHEMBL3899262 | 0.80 | MEN1 (0.37) | LPAR3LPAR1LPAR2FDPSMEN1 | |
| SCHEMBL9115357 | 0.80 | TSHR (0.46) | LPAR3LPAR1LPAR2FDPSLMNA | |
| SCHEMBL16021684 | 0.79 | LMNA (0.35) | LPAR3LPAR1LPAR2LMNA | |
| SCHEMBL16021693 | 0.79 | FDPS (0.38) | FDPSLMNA | |
| SCHEMBL16021698 | 0.79 | LMNA (0.35) | LPAR3LPAR1LPAR2LMNA | |
| SCHEMBL26250154 | 0.77 | LMNA (0.33) | LMNA | |
| SCHEMBL12267299 | 0.77 | CHRM2 (0.32) | LPAR3LPAR1LPAR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653141-B2 | HIV protease inhibiting compounds | ABBVIE INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| US-8193227-B2 | HIV protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2012-06-05 | — | — | US | disclosed |
| US-20110003827-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003827-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | LPAR3 4160/4885LPAR1 4226/4885LPAR2 4577/4885 |
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | SERPINB1, HPN, DNPEP | LPAR3 4160/4885LPAR1 4226/4885LPAR2 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.